Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes

AIMS: The EMPA‐REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca(2+)‐dependent activation of Ca(2+)/calmodulin‐dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfun...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESC Heart Fail
Autors principals: Mustroph, Julian, Wagemann, Olivia, Lücht, Charlotte M., Trum, Maximilian, Hammer, Karin P., Sag, Can Martin, Lebek, Simon, Tarnowski, Daniel, Reinders, Jörg, Perbellini, Filippo, Terracciano, Cesare, Schmid, Christof, Schopka, Simon, Hilker, Michael, Zausig, York, Pabel, Steffen, Sossalla, Samuel T., Schweda, Frank, Maier, Lars S., Wagner, Stefan
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073019/
https://ncbi.nlm.nih.gov/pubmed/30117720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12336
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars